Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for human tumor stem cell drug sensitivity assays, effective May 15, 2026. Here's what billing teams need to know before claims start moving through the system.
This policy governs whether Medicare will pay for laboratory assays that test a patient's tumor cells against various chemotherapy agents to predict drug response. The CMS human tumor stem cell drug sensitivity assay coverage policy has a long history — and it has never been favorable to providers who bill these services. The effective date of May 15, 2026 means your billing team should act now, not after the first denial lands. The policy does not list specific CPT or HCPCS codes in the data available at publication, but the clinical scope is clear enough to guide your audit.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Human Tumor Stem Cell Drug Sensitivity Assays |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | 2026-05-15 |
| Impact Level | High |
| Specialties Affected | Oncology, Hematology/Oncology, Clinical Laboratory, Pathology |
| Key Action | Audit any pending or future claims for tumor chemosensitivity or chemo-resistance testing before May 15, 2026 |
CMS Human Tumor Stem Cell Drug Sensitivity Assay Coverage Criteria and Medical Necessity Requirements 2026
The core issue with human tumor stem cell drug sensitivity assays — also called chemosensitivity assays or chemo-resistance assays — is that CMS has long viewed them as lacking sufficient clinical evidence to meet the medical necessity standard for Medicare reimbursement.
These assays work by culturing a patient's live tumor cells and exposing them to various chemotherapy drugs. The goal is to identify which agents are most likely to be effective and which the tumor is resistant to. Sounds useful. The problem is that decades of clinical evidence have failed to show that using these test results to guide treatment actually improves patient outcomes compared to standard oncology judgment.
CMS ties Medicare coverage to demonstrated clinical utility — not just analytical validity or even clinical validity. A test can work exactly as designed and still not qualify for coverage if the evidence doesn't show it changes outcomes in a meaningful way. That's the gap these assays have never closed with CMS.
Under this modified coverage policy, the medical necessity bar for human tumor stem cell drug sensitivity assays remains extremely high — effectively prohibitive for most clinical scenarios. Your team should treat these assays as non-covered under Medicare unless a specific, documented exception applies in a given Medicare Administrative Contractor jurisdiction.
Whether prior authorization is required before performing or billing these assays depends on how your MAC handles the policy locally. Check your MAC's local coverage determination (LCD) before assuming national policy is the only word on the matter. Some MACs have issued their own LCDs that go further than the national policy, and some have additional documentation requirements even for denied services that affect how you write off the claim.
CMS Human Tumor Stem Cell Drug Sensitivity Assay Exclusions and Non-Covered Indications
The non-covered designation here is broad. CMS does not consider human tumor stem cell drug sensitivity assays medically necessary for guiding chemotherapy selection in cancer treatment. This applies regardless of tumor type, cancer stage, or the treating oncologist's preference.
The underlying reason is clinical utility. CMS's position is that no sufficient evidence base exists to show that using these assay results changes treatment decisions in ways that improve survival, reduce toxicity, or produce better patient outcomes. Until that evidence exists in a form CMS accepts, reimbursement is off the table.
This is not a coverage gap that prior authorization fills. Prior auth exists for services that are covered but require gatekeeping. These assays don't clear the coverage threshold in the first place. Billing them to Medicare expecting payment — even with prior auth — sets up a claim denial and potential compliance exposure.
Oncology practices that use these assays for clinical decision-making are free to do so. The billing question is separate. If you're performing the assay, you need a clear financial responsibility agreement with the patient before the service, because Medicare won't pay and the patient may be liable depending on how the ABN was handled.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Chemosensitivity assay to guide chemotherapy selection — any tumor type | Not Covered | Not specified in policy data | CMS considers this not medically necessary; lacks demonstrated clinical utility |
| Chemo-resistance assay to predict drug resistance — any tumor type | Not Covered | Not specified in policy data | Same clinical utility standard applies |
| Human tumor stem cell culture and drug sensitivity testing — laboratory performed | Not Covered | Not specified in policy data | Applies to Medicare beneficiaries; MAC LCDs may add further restrictions |
| Tumor stem cell assay billed under investigational or research context | Not Covered for routine billing | Not specified in policy data | Clinical trial billing rules apply separately — consult your compliance officer |
CMS Human Tumor Stem Cell Drug Sensitivity Assay Billing Guidelines and Action Items 2026
This policy change is a modification, not a new policy. That means CMS reviewed the existing coverage position and updated it — possibly tightening language, adding clarification, or revising the clinical rationale. Without full policy text available at publication, your team should pull the source document directly at the link above and compare it line by line against the prior version.
Here are the actions your billing team should take before May 15, 2026:
| # | Action Item |
|---|---|
| 1 | Pull the full policy text from CMS. Go to the source document at the link above. Read the updated policy against whatever version your team currently has on file. The change type is "Modified" — which means something specific changed. You need to know what. |
| 2 | Audit claims billed in the past 12 months for tumor chemosensitivity or chemo-resistance testing. If your practice or lab has been billing these assays to Medicare, check whether any were paid, denied, or are pending. A modification to the coverage policy can signal that CMS is tightening enforcement, not just updating language. |
| 3 | Check your MAC's LCD for any additional local guidance. The national policy sets the floor. Your Medicare Administrative Contractor may have issued an LCD that goes further — with more specific non-covered codes, documentation requirements, or claims submission rules. If you don't know your MAC's position, call their provider outreach line or check their website. |
| 4 | Review your ABN process for these services. If your oncology or lab team performs these assays on Medicare patients, an Advance Beneficiary Notice of Noncoverage is required before the service when you expect Medicare will deny the claim. An incomplete or missing ABN means the patient can't be billed either. Fix this process before May 15. |
| 5 | Update your charge capture and superbill to flag these assays. Every time a human tumor stem cell drug sensitivity assay gets ordered for a Medicare patient, your billing team needs to see it before it goes out the door. Build a flag into your workflow — not a reminder email, an actual hard stop in your charge capture system. |
| 6 | Talk to your compliance officer before billing under any gray-area clinical scenario. If your practice thinks a specific patient situation might qualify for coverage under this policy, don't bill and hope. Discuss it with your compliance officer first. Human tumor stem cell drug sensitivity assay billing has compliance exposure that goes beyond a single claim denial — repeated billing for non-covered services can trigger audits. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Human Tumor Stem Cell Drug Sensitivity Assays Under This Policy
The policy data available at publication does not list specific CPT, HCPCS, or ICD-10 codes. Do not let that gap stop your audit.
Human tumor stem cell drug sensitivity assay billing typically falls under laboratory CPT codes in the molecular pathology and genomic sequencing ranges, as well as older chemosensitivity-specific codes. However, since the policy document does not specify codes, your billing team should not rely on this post to define the code set. Pull the full policy document from the CMS source link and identify the exact codes CMS references in the updated text.
If your billing guidelines documentation reference tool doesn't surface this policy against specific codes, that's a gap worth addressing. A policy that doesn't list codes can still affect reimbursement — CMS contractors audit by service description and clinical context, not just code matching.
What to Do Without a Published Code List
- Search your lab or oncology charge master for any service described as "chemosensitivity," "chemo-resistance," "tumor stem cell," or "drug sensitivity assay"
- Cross-reference those charges against your Medicare payer contracts and LCD database
- If you find codes in your system that map to these services, flag them for review against this updated policy before May 15, 2026
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.